Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ani Pharmaceuticals (ANIP) Other Operating Expenses (2016 - 2025)

Historic Other Operating Expenses for Ani Pharmaceuticals (ANIP) over the last 16 years, with Q3 2025 value amounting to -$295000.0.

  • Ani Pharmaceuticals' Other Operating Expenses changed N/A to -$295000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $291.3 million, marking a year-over-year increase of 4425.2%. This contributed to the annual value of $312.2 million for FY2024, which is N/A changed from last year.
  • According to the latest figures from Q3 2025, Ani Pharmaceuticals' Other Operating Expenses is -$295000.0.
  • In the past 5 years, Ani Pharmaceuticals' Other Operating Expenses registered a high of $108.6 million during Q4 2024, and its lowest value of -$8.4 million during Q2 2021.
  • Its 5-year average for Other Operating Expenses is $52.3 million, with a median of $58.0 million in 2023.
  • Per our database at Business Quant, Ani Pharmaceuticals' Other Operating Expenses plummeted by 12446.91% in 2021 and then surged by 67232.14% in 2022.
  • Ani Pharmaceuticals' Other Operating Expenses (Quarter) stood at -$350000.0 in 2021, then surged by 13835.71% to $48.1 million in 2022, then skyrocketed by 46.85% to $70.6 million in 2023, then surged by 53.81% to $108.6 million in 2024, then tumbled by 100.27% to -$295000.0 in 2025.
  • Its Other Operating Expenses was -$295000.0 in Q3 2025, compared to $99.2 million in Q2 2025 and $83.8 million in Q1 2025.